Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
85253 trials found · Page 46 of 4263
-
New 'Living Drug' trial offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies. A bayesian optimal interval (BOIN) 12 design will be used to explore the optimal biological dose (OBD) from startin…
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
New hope for lung cancer patients after immunotherapy fails
Disease control Recruiting nowThis is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based t…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New 'Living Drug' trial targets aggressive cancers
Disease control Recruiting nowBackground: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 16, 2026 13:02 UTC
-
New hope for kids with tough leukemia: pioneering cell therapy trial begins
Disease control Recruiting nowThe goal of this clinical trial is to test the feasibility and safety of an academic production of two different anti-CD19 chimeric antigen receptor T cells (CART) products according to the different biomarkers of the disease in children and young adults with relapsed/refractory …
Phase: PHASE1 • Sponsor: Instituto de Investigación Hospital Universitario La Paz • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
New targeted drug joins fight against advanced lung cancer
Disease control Recruiting nowThis study is an open-label, randomized, controlled, multicenter Phase IIIb clinical study, aiming to evaluate the efficacy, safety, and tolerability of Vebreltinib Enteric Capsule combined with platinum-based doublet chemotherapy compared with platinum-based doublet chemotherapy…
Phase: PHASE3 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control
Last updated Apr 14, 2026 13:10 UTC
-
Gene therapy trial hopes to quiet seizures in kids with rare STXBP1 brain disease
Disease control TerminatedThe goal of this clinical trial is to learn about the safety of CAP-002 gene therapy in children with Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy. It will also provide information about whether CAP-002 demonstrates efficacy in treating children with STXBP1 with and without…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
Major trial aims to save lives from rare heart disease
Disease control Recruiting nowThe purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the …
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
Radical cell therapy tested for Hard-to-Treat autoimmune conditions
Disease control ENROLLING_BY_INVITATIONThis study will have two Phases: Phase 1a and Phase 1b. The goal of this clinical study is to learn more about the study drug KITE-363, to establish dosing, tolerability, safety, and preliminary efficacy of KITE-363 in participants with refractory autoimmune diseases. The primar…
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Apr 13, 2026 20:09 UTC
-
Stem cell breakthrough trial seeks to repair spinal cord damage
Disease control Recruiting nowThis Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury
Phase: PHASE1 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
Spinal implant trial offers hope for paralyzed patients to walk again
Disease control Recruiting nowThe primary objective of this clinical trial is to investigate the efficacy of Epidural Electrical Stimulation (EES) in restoring motor and sensory function in patients with chronic spinal cord injury (SCI) at levels T11-L3, classified as ASIA B-D. The study aims to address the f…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Life-Saving tourniquet tested for mothers with unstoppable bleeding
Disease control Recruiting nowThis multicenter study aims to evaluate effectiveness and safety of using the AAJT-S device as a temporary intervention for severe, atony-related PPH that is refractory to standard therapies
Phase: NA • Sponsor: LLC UkrMedGroup • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
Brain flush trial aims to slash high death rate from severe infection
Disease control Recruiting nowVentriculitis is a severe infectious disease of the central nervous system with diverse etiologies. Currently, the treatment for ventriculitis is challenging, with poor prognosis. The mortality rate of ventriculitis is generally reported to be higher than 30%, with the highest re…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Apr 07, 2026 14:35 UTC
-
Radioactive drug trial offers new hope for Tough-to-Treat prostate cancer
Disease control Recruiting nowThe purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investiga…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 06, 2026 14:06 UTC
-
New hope for kids with Tough-to-Treat lymphoma
Disease control Recruiting nowThe purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.
Phase: PHASE2, PHASE3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New cell therapy shows promise for Late-Stomach cancer patients
Disease control Recruiting nowThis project employs a prospective, double-blind, randomized controlled trial methodology to comparatively analyze the safety and survival outcomes of human umbilical cord blood RAK cells applied in advanced gastric cancer. Firstly, the maximum tolerated dose (MTD) of RAK cell th…
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Apr 23, 2026 21:11 UTC
-
Immune cell boost may keep leukemia at bay after transplant
Disease control Recruiting nowThis is an investigator-initiated clinical trial evaluating the safety and efficacy of allogeneic γδ T cell infusion for relapse prevention in high-risk acute myeloid leukemia patients after transplantation.
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
New 'Living Drug' trial offers hope for tough blood cancers
Disease control Recruiting nowThis study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the tre…
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
New hope for fighting lung cancer brain tumors
Disease control Recruiting nowFor non-small cell lung cancer brain metastases, stereotactic radiotherapy is gradually replacing whole brain radiotherapy as the standard treatment. When patients have multiple brain metastases or larger tumors (diameter\>2cm), single session stereotactic radiotherapy (SRS) may …
Phase: PHASE3 • Sponsor: Sun Yat-Sen University Cancer Center • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
New hope for kids with rare brain disease in Final-Stage drug trial
Disease control Recruiting nowAn 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease
Phase: PHASE3 • Sponsor: Azafaros A.G. • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
Race against time: new pill aims to slow devastating childhood brain disease
Disease control Recruiting nowAn 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis
Phase: PHASE3 • Sponsor: Azafaros A.G. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC